@article{61abce6b1c37404b8704b4ab84959a84,
title = "An increase in CD62Ldim neutrophils precedes the development of pulmonary embolisms in COVID-19 patients",
abstract = "OBJECTIVES: A high incidence of pulmonary embolism (PE) is reported in patients with critical Corona Virus Disease 2019 (COVID-19). Neutrophils may contribute to this through a process referred to as immunothrombosis. The aim of this study was to investigate the occurrence of neutrophil subpopulations in blood preceding the development of COVID-19 associated PE.METHODS: We studied COVID-19 patients admitted to the ICU of our tertiary hospital between 19-03-2020 and 17-05-2020. Point-of-care fully automated flow cytometry was performed prior to ICU admission, measuring the neutrophil activation/maturation markers CD10, CD11b, CD16 and CD62L. Neutrophil receptor expression was compared between patients who did or did not develop PE (as diagnosed on CT angiography) during or after their ICU stay.RESULTS: Among 25 eligible ICU patients, 22 subjects were included for analysis, of whom nine developed PE. The median (IQR) time between neutrophil phenotyping and PE occurrence was 9 (7-12) days. A significant increase in the immune-suppressive neutrophil phenotype CD16bright /CD62Ldim was observed on the day of ICU admission (p=0.014) in patients developing PE compared to patients who did not.CONCLUSION: The increase in this neutrophil phenotype indicates that the increased number of CD16bright /CD62Ldim neutrophils might be used as prognostic marker to predict those patients that will develop PE in critical COVID19 patients.",
keywords = "CD62L, COVID-19, Intensive Care Unit, L-selectin, Neutrophils, pulmonary embolism, SARS-CoV-2, Thrombosis",
author = "Roy Spijkerman and Jorritsma, {Nikita Kn} and Bongers, {Suzanne H} and Bindels, {Bas Jj} and Jukema, {Bernard N} and Lillian Hesselink and Falco Hietbrink and Leenen, {Luke Ph} and {van Goor}, {Harri{\"e}t Mr} and N Vrisekoop and Kaasjager, {Karin Ah} and Leo Koenderman and Olaf Cremer",
note = "Funding Information: The AQUIOS CL? ?load & go? flow cytometer is provided by the company Beckman Coulter Life Sciences, Miami, FL, USA. All authors declare that there are no other competing interests. This article was supported by a grant (grant # 400.17.604) of the Dutch Research Council (NWO) in the framework of the ?Startimpulse? Dutch National Research Agenda (NWA) and by Health Holland (grant # 20064) For technical support, we want to thank Paul van Hoof, Roelof-Jan van der Lei, Geert Weijers, Andreas Boehmler and Markus Kaymer from the Beckman Coulter team. We especially want to thank Coen Maas and Olaf Cremer for critically reading the manuscript. Funding Information: The AQUIOS CL {\textquoteleft}load & go{\textquoteright} flow cytometer is provided by the company Beckman Coulter Life Sciences, Miami, FL, USA. All authors declare that there are no other competing interests. This article was supported by a grant (grant # 400.17.604 of the Dutch Research Council (NWO) in the framework of the {\textquoteleft}Startimpulse{\textquoteright} Dutch National Research Agenda (NWA) and by Health Holland (grant # 20064) {\textregistered} ) Publisher Copyright: {\textcopyright} 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.",
year = "2021",
month = jun,
doi = "10.1111/sji.13023",
language = "English",
volume = "93",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell",
number = "6",
}